Intervention Protocol

You have free access to this content

Treatment for osteoporosis in people with ß-thalassaemia

  1. Amit Bhardwaj1,
  2. Kye Mon Min Swe2,*,
  3. Nirmal Kumar Sinha1,
  4. Ifeyinwa Osunkwo3

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 28 MAR 2013

Assessed as up-to-date: 1 FEB 2013

DOI: 10.1002/14651858.CD010429


How to Cite

Bhardwaj A, Swe KMM, Sinha NK, Osunkwo I. Treatment for osteoporosis in people with ß-thalassaemia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD010429. DOI: 10.1002/14651858.CD010429.

Author Information

  1. 1

    Melaka-Manipal Medical College (MMMC), Department of Orthopaedics, Melaka, Melaka, Malaysia

  2. 2

    Melaka-Manipal Medical College (MMMC), Department of Community Medicine, Melaka, Malaysia

  3. 3

    Aflac Cancer and Blood Disorders Service, Emory University School of Medicine, Comprehensive Sickle Cell Program, Atlanta, Georgia, USA

*Kye Mon Min Swe, Department of Community Medicine, Melaka-Manipal Medical College (MMMC), Jalan Batu Hampar, Bukit Baru, Melaka, 75150, Malaysia. khmoneminswe@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 28 MAR 2013

SEARCH

References

Additional references

Akesson 2003
Anapliotou 1995
Angastiniotis 1998
Athanasios 2007
  • Christoforidis A, Kazantzidou E, Tsatra I, Tsantali H, Koliakos G, Hatzipantelis E, et al. Normal lumbar bone mineral density in optimally treated children and young adolescents with β-thalassaemia major. Hormones 2007;6(4):334-40.
Basanagoudar 2001
  • Basanagoudar PL, Gill SS, Dhillon MS, Marwaha RK. Fractures in transfusion dependent beta thalassemia--an Indian study. Singapore Medical Journal 2001;42(5):196-9.
Borgna-Pignatti 2007
Canatan 1995
Christoforidis 2007
  • Christoforidis A,  Kazantzidou E,  Tsatra I,  Tsantali H,  Koliakos G,  Hatzipantelis E,  et al. Normal lumbar bone mineral density in optimally treated children and young adolescents with beta-thalassaemia major. Hormone 2007;6(4):334-40.
De Sanctis 1996
  • De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, et al. Growth and development in thalassaemia major patients with bone lesion due to desferrioxamine. European Journal of Pediatrics 1996;155(5):368-72.
Donner 2001
Elbourne 2004
  • Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Fleisch 1997
  • Fleisch H. Mechanisms of action of the bisphosphonates. Medicina (B Aires) 1997;57(Suppl 1):65-75.
Galanello 2010
Gaudio 2008
  • Gaudio A, Morabito N, Xourafa A, Macrì I, Meo A, Morgante S, et al. Bisphosphonates in the treatment of thalassemia-associated osteoporosis. Journal of Endocrinological Investigation 2008;31(2):181-4.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
Jensen 1998a
  • Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, et al. High incidence of osteoporosis in thalassaemia major. Journal of Pediatric Endocrinology and Metabolism 1998;11(3):975-7.
Jensen 1998b
Lindsay 1993
Mokhtar 2011
  • Mokhtar GM,  Tantawy AA,  Adly AA,  Ismail EA. Clinicopathological and radiological study of Egyptian β-thalassemia intermedia and β-thalassemia major patients: relation to complications and response to therapy. Hemoglobin 2011;35(4):382-405.
Morabito 2002
Pennisi 2003
  • Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE. Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. Journal of Bone and Mineral Metabolism 2003;21(6):402-8.
Perifanis 2004
  • Perifanis V,  Vyzantiadis T,  Vakalopoulou S,  Tziomalos K,  Garypidou V,  Athanassiou-Metaxa M,  et al. Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. British Journal of Haematology 2004;125(1):91-2.
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Ruggierol 1998
  • Ruggiero L, De Sanctis V. Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients. Journal of Pediatric Endocrinology & Metabolism 1998;11(Suppl 3):3773-8.
Scacchi 2008
Shamshirsaz 2007
  • Shamshirsaz AA,  Bekheirnia MR,  Kamgar M,  Pakbaz Z,  Tabatabaie SM,  Bouzari N,  et al. Bone mineral density in Iranian adolescents and young adults with beta-thalassemia major. Pediatric Hematology and Oncology 2007;24(7):469-79.
Suda 1997
Sutipornpalangkul 2010
  • Sutipornpalangkul W, Janechetsadatham Y, Siritanaratkul N, Harnroongroj T. Prevalence of fractures among Thais with thalassaemia syndromes. Singapore Medical Journal 2010;51(10):817-21.
Vichinsky 1998
Vichinsky 2005
Vogiatzi MG 2006
  • Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, et al. Prevalence of fractures among the Thalassemia syndromes in North America. Bone 2006;38(4):1-5.
Vokaridou 2004
Weatherall 1995
  • Weatherall DJ. The Thalassemias. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ editor(s). Williams Hematology. 5th Edition. McGraw-Hill Book Company, 1995:581-615.
WHO 1994
  • World Health Organisation. Assessment of fracture risk and its implication to screening for postmenopausal osteoporosis: Technical report series 843. http://whqlibdoc.who.int/trs/WHO_TRS_843.pdf (accessed 04 January 2012).
Wonke 1998
Wonke 2001